Fig. 1 | Scientific Reports

Fig. 1

From: Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities

Fig. 1

Generation of ribocilcib, abemaciclib and palbociclib resistant T47D and MCF7 cell lines: T47D and MCF7 was treated with increasing doses of ribociclib, abemaciclib, or palbociclib (50–600 nM). Please see methods section for full details. The figure was created in BioRender [Algethami, M. (2025) https://BioRender.com/bns6ond].

Back to article page